Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P01344
UPID:
IGF2_HUMAN
Alternative names:
Somatomedin-A; T3M-11-derived growth factor
Alternative UPACC:
P01344; B3KX48; B7WP08; C9JAF2; E3UN45; P78449; Q14299; Q1WM26; Q9UC68; Q9UC69
Background:
Insulin-like growth factor II (IGF2), also known as Somatomedin-A, plays a pivotal role in growth and development. It is a major fetal growth hormone in mammals, crucial for fetoplacental development and involved in tissue differentiation. In adults, IGF2 is key in glucose metabolism across various tissues. It acts as a ligand for integrin, essential for IGF2 signaling, and supports muscle differentiation by regulating MYOD1 function.
Therapeutic significance:
IGF2's involvement in Silver-Russell syndrome, characterized by growth retardation and craniofacial features, highlights its therapeutic potential. Understanding IGF2's role could open doors to novel strategies for managing growth-related disorders.